SCHEMBL4299959

SCHEMBL4299959

CNCc1csc(NC(C)=O)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.69
KMT2A Q03164 1/20 0.69
AOC3 Q16853 6/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
CDK5 Q00535 7/20 0.55
CDK5R1 Q15078 7/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
CCNE2 O96020 1/20 0.53
CCNE1 P24864 1/20 0.53
CDK2 P24941 1/20 0.53
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CASP3 P42574 1/20 0.51
HTT P42858 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
MAOB P27338 3/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367981 0.87 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL3933173 0.83 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL2612387 0.83 SMN1; SMN2 (0.73) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL17977308 0.81 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL1939115 0.81 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL11202231 0.81 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL4068199 0.81 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL307301 0.81 SMN1; SMN2 (1.00) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL3904033 0.81 SMN1; SMN2 (0.65) SMN1; SMN2KMT2AAOC3NPC1RAB9A
SCHEMBL10864306 0.80 AOC3 (0.60) SMN1; SMN2KMT2AAOC3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997024-B1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2018-03-28 EP disclosed
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
CN-101421265-A Thiazole compounds as protein kinase b (pkb) inhibitors AMGEN INC (US) 2009-04-29 CN disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1981884-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS Amgen, Inc (US) 2008-10-22 EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 SMN1; SMN2 2808/4885KMT2A 3711/4885AOC3 4394/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 SMN1; SMN2 3662/4885KMT2A 3968/4885AOC3 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.